Preeclampsia Clinical Trial
Official title:
The Correlation Between Vitamin A / E Levels and Preeclampsia.
Vitamin A (VA) and vitamin E (VE) are fat-soluble vitamins and indispensable substances in
life activities.
VA plays an important role in visual function, normal formation and development of epithelial
cells, development and growth of bones, immune function and reproductive health. VA is of
great significancCe for the growth and development of embryonic cells, especially for the
development of fetal vertebrae, spinal cord, limbs, heart, eyes and ears. The lack of
maternal VA will lead to the stunted development of fetal organs and tissues, and even fetal
developmental malformation. In addition, VA has a protective effect on neonatal lung
maturation.VA deficiency can cause the decrease in the activity of enzymes needed to catalyze
the formation of progesterone precursors in pregnant women, reduce the production of steroids
in adrenal glands, gonads and placenta, and seriously affect the functions of multiple organs
such as heart, liver and skeletal muscle in pregnant women.
VE, also known as tocopherol, has non-enzymatic antioxidant function, and maintains the
balance of REDOX reaction in vivo by efficiently removing free radicals generated by lipid
peroxidation.VE can increase the synthesis of nitric oxide (NO) in endothelial cells and
improve vascular endothelial function. Long-term administration of VE can improve the
impaired endothelium-dependent vasodilatory function in patients.VE can promote sex hormone
secretion, improve fertility and prevent abortion. Pregnancy women the body's metabolism,
increases produce free radicals, lipid peroxidation, low levels of VE will result in the
accumulation of excess free radicals, cause the placenta aging, vascular endothelial damage,
increase the risk of the occurrence of PHI and adverse outcome rate, as well as the membranes
of cell membrane damage, increase the risk of premature rupture of membranes.
Gestational hypertension is a group of diseases with both pregnancy and elevated blood
pressure, and is the main cause of increased maternal and perinatal mortality, mainly
including gestational hypertension, preeclampsia PE, and eclampsia, as well as chronic
hypertension with preeclampsia and chronic hypertension with pregnancy. The cause of PE is
unknown, but studies have found that it may be related to insufficient recast of spiral
uterine arterioles, excessive activation of inflammatory immune system, damage of vascular
endothelial cells, genetic factors, nutritional deficiency and insulin resistance. Recent
studies have found that free radical oxidative damage may also be one of the main reasons for
the occurrence and development of PE. PE occurs, the placenta bed vasospasm, ischemia,
angiogenesis blocking and endothelial atherosclerotic changes, local immune cell activity,
make produce free radicals increases, interfere with the vascular endothelial cell function,
reduce vascular relaxation material synthesis, and shrink blood vessels increase material
synthesis, promote vascular spasm, platelet condensed state is changed, thus appeared a
series of PE.
Previous studies have shown that oxygen free radicals and lipid peroxides are increased in
PHI patients, while the levels of VA and VE are closely related to the antioxidant capacity
of the body, and their lack can lead to the imbalance of the homeostasis of redox reaction in
multi-tissue cells in the body. Since both VA and VE belong to fat-soluble vitamins and are
widely distributed in daily food, whether their effects on the occurrence and development of
PE are independent or combined will be a question for us to explore. Therefore, this study
intends to evaluate the correlation between VA, VE and VA+VE and PE occurrence through
multi-center clinical studies, and explore and summarize the feasibility of VA and VE in PE
adjuvant treatment.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | January 1, 2022 |
Est. primary completion date | January 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Age 18-45 years of natural pregnancy, early pregnancy without threatened abortion and infection 2. No history of hypertension, diabetes, heart disease and other internal and surgical diseases 3. Pregnancy are normal to take folic acid and calcium tablets, did not take other drugs 4. Agree to participate in the experiment and sign the informed consent Exclusion Criteria: 1. Refuse to sign or request to withdraw the informed consent midway 2. Serious adverse events, allergies or intolerance 3. Poor patient compliance, refused to cooperate with the experimental requirements |
Country | Name | City | State |
---|---|---|---|
China | The second affiliated hospital of medical college of zhejiang university | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To compare the serum VA and VE levels between normal pregnant women and pre-eclampsia pregnant women | To compare the serum VA and VE levels between normal pregnant women and pre-eclampsia pregnant women | change from 20 to 37 weeks | |
Primary | To compare the levels of VA and VE in pregnant women with mild and severe preeclampsia | To compare the levels of VA and VE in pregnant women with mild and severe preeclampsia | change from 20 to 37 weeks | |
Primary | To analyze the changes in serum levels of VA and VE in pregnant women with mild and severe preeclampsia, as well as the effects of independent and combined intake of VA and VE on the disease | To analyze the changes in serum levels of VA and VE in pregnant women with mild and severe preeclampsia, as well as the effects of independent and combined intake of VA and VE on the disease | change from 20 to 37 weeks | |
Primary | To analyze the correlation between serum VA and VE levels in the case group and important indicators related to the disease (such as blood pressure, body weight, hematuria routine, liver and kidney function, etc.) . | To analyze the correlation between serum VA and VE levels in the case group and important indicators related to the disease (such as blood pressure, body weight, hematuria routine, liver and kidney function, etc.) . | change from 20 to 37 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |